Literature DB >> 34463284

Vascular skin manifestations in patients with severe COVID-19 in intensive care units: a monocentric prospective study.

Frédéric Dezoteux1, Baptiste Mille2, Charlotte Fievet2, Anne-Sophie Moreau3, Alain Duhamel4, Elodie Drumez4, Daniel Mathieu3, Julien Poissy3, Delphine Staumont-Salle1, Sébastien Buche2.   

Abstract

Various skin manifestations have been reported during the coronavirus disease 2019 (COVID-19) pandemic. Among these are acral vascular skin lesions in non-severe patients, but few studies have focused specifically on patients with severe COVID-19 admitted to the intensive care unit (ICU) We aimed to assess the frequency of acral vascular skin manifestations (AVSM) in patients admitted to the ICU based on systematic dermatological examination We conducted a clinical, observational and prospective study in the ICU of Lille University Hospital (France). All adult patients with RT-PCR-confirmed severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection were included on May 5th and 6th, 2020 A total of 39 patients with severe COVID-19 were examined (34 males and five females; median age: 61 [55-59]). We observed AVSM in 11/39 patients (28%) including five with acral necrotic lesions, three with haemorrhagic blisters, one with acral livedoid rash, and one with erosive distal lesions. Chilblain or chilblain-like lesions were not seen, unlike ambulatory or non-severe patients described in the literature. There was no difference regarding the median length of stay in the ICU, initial symptoms of COVID-19 or baseline characteristics, except for a lower BMI in patients with AVSM. All patients had biological coagulation abnormalities (e.g. higher levels of fibrinogen or D-dimers), but there was no difference between patients with and without AVSM AVSM are infrequent and heterogenous and seem to be non-specific to patients with severe SARS-CoV-2, and possibly unrelated to COVID-19. The pathophysiology of AVSM described during the COVID-19 pandemic is not fully elucidated.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; chilblain; coronavirus; intensive care unit; vascular skin manifestations

Year:  2021        PMID: 34463284      PMCID: PMC8572689          DOI: 10.1684/ejd.2021.4107

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   2.805


  20 in total

1.  Cutaneous manifestations in COVID-19: a first perspective.

Authors:  S Recalcati
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05       Impact factor: 6.166

2.  Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings.

Authors:  Athanassios Kolivras; Florence Dehavay; Daphné Delplace; Francesco Feoli; Isabelle Meiers; Laurenzo Milone; Catherine Olemans; Ursula Sass; Anne Theunis; Curtis T Thompson; Laura Van De Borne; Bertrand Richert
Journal:  JAAD Case Rep       Date:  2020-04-18

3.  COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure.

Authors:  Luca Spiezia; Annalisa Boscolo; Francesco Poletto; Lorenzo Cerruti; Ivo Tiberio; Elena Campello; Paolo Navalesi; Paolo Simioni
Journal:  Thromb Haemost       Date:  2020-04-21       Impact factor: 5.249

4.  Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis.

Authors:  Mi Xiong; Xue Liang; You-Dong Wei
Journal:  Br J Haematol       Date:  2020-05-14       Impact factor: 6.998

5.  Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York.

Authors:  Leonidas Palaiodimos; Damianos G Kokkinidis; Weijia Li; Dimitrios Karamanis; Jennifer Ognibene; Shitij Arora; William N Southern; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-05-16       Impact factor: 8.694

6.  Comment on "Characterization of acute acro-ischemic lesions in non-hospitalized patients: A case series of 132 patients during the COVID-19 outbreak".

Authors:  Diego Fernandez-Nieto; Juan Jimenez-Cauhe; Ana Suarez-Valle; Oscar M Moreno-Arrones; David Saceda-Corralo; Arantxa Arana-Raja; Daniel Ortega-Quijano
Journal:  J Am Acad Dermatol       Date:  2020-06-01       Impact factor: 11.527

7.  Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature.

Authors:  S Matar; B Oulès; P Sohier; O Chosidow; M Beylot-Barry; N Dupin; S Aractingi
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-20       Impact factor: 9.228

8.  Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy.

Authors:  P Del Giudice; D Boudoumi; B Le Guen; M Reverte; J Gutnecht; J P Lacour; J P Kraemer; A Motard; M Roa
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-22       Impact factor: 9.228

Review 9.  Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control.

Authors:  Cheryl Yi-Pin Lee; Raymond T P Lin; Laurent Renia; Lisa F P Ng
Journal:  Front Immunol       Date:  2020-04-24       Impact factor: 7.561

Review 10.  Cutaneous signs in COVID-19 patients: A review.

Authors:  Uwe Wollina; Ayşe Serap Karadağ; Christopher Rowland-Payne; Anca Chiriac; Torello Lotti
Journal:  Dermatol Ther       Date:  2020-05-29       Impact factor: 2.851

View more
  1 in total

1.  Should we look beyond the interferon signature in chilblain-like lesions associated with COVID-19?

Authors:  S M Pilkington; R E B Watson
Journal:  Br J Dermatol       Date:  2021-11-08       Impact factor: 11.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.